Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

ABSTRACT:

Background & aims

It is recommended that patients with chronic hepatitis C virus (HCV) genotype 3 infections receive 24 weeks of treatment. A rapid virologic response (RVR; at week 4) predicts a sustained virologic response (SVR), although not all patients with an RVR achieve an SVR. We explored the relationships among hepatic steatosis, level of HCV RNA, relapse, and RVR in a phase 3 randomized controlled trial of 932 patients infected with HCV genotype 2 (n = 427) or 3 (n = 505) who received 24 weeks of therapy with interferon-α.

Methods

In patients with an RVR (HCV RNA <43 IU/mL), the presence of an SVR was modeled using multivariate logistic regression as a function of age, sex, weight, body mass index, insulin resistance, steatosis, and levels of γ-glutamyl transpeptida

SUBMITTER: Shah SR 

PROVIDER: S-EPMC3155986 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature